Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2013

View Archived Issues

A comparative analysis of the structural-antifungal activity of polyene antibiotics

TRK-390 as a novel and highly selective phosphate binder

Results presented for olaparib in EGFR NSCLC and BRCA-mutated ovarian cancer

LC-510201, a new S1P1/S1P5 receptor agonist for multiple sclerosis

AnGes' phase I/II study of HGF gene therapy in primary lymphedema begins in Japan

First-in-human data for the human monoclonal antibody KRN-23

Presentations describe preclinical data on hepatitis B treatment candidate bentysrepinine

HSV-2 vaccine protective in animal challenge model

Novel myostatin inhibitors patented

Vitae Pharmaceuticals presents new liver X receptor-beta agonists

Novel metabotropic glutamate mGlu2 receptor PAMs disclosed by Bristol-Myers Squibb

Dual orexin receptor antagonists discovered at Rottapharm

ConfirmMDx prostate cancer test meets primary endpoints in clinical validation study

Joslin Diabetes Center partners with Pfizer and Lilly

Researchers use DNA nanotechnology to develop super-high-resolution molecular imaging

Poxel reports data for imeglimin from human hyperglycemic clamp trial

FDA accepts IND application for LGD-6972 in type 2 diabetes

Ampio Pharmaceuticals reports results from independent panel review of Optina trial

GSK adds development candidate to its collaboration with Isis

Kitasato Institute and Tella to collaborate on dendritic cell vaccine study

Effimune and Janssen Biotech sign option and license agreement for FR-104

Immutep and Eddingpharm sign agreement for ImmuFact IMP-321 in China

Chugai seeks approval of alectinib hydrochloride in Japan

Eleison initiates phase III study of glufosfamide for second-line treatment of pancreatic cancer

Phase II study of Novavax's respiratory syncytial virus vaccine begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...